Spiriva
(Tiotropium Bromide)ApprovedSmall molecule
Boehringer IngelheimTiotropium bromide is used to treat chronic obstructive pulmonary disease (COPD) and asthma by helping to relax and open airways in the lungs, making it easier to breathe.[2] Spiriva is currently approved and in use across 6 indications[4].[1]
Spiriva is one of 103 small molecule programs targeting Emphysema. It is currently in Approved.
6
Indications
52
Total Trials
0
Active Trials
102
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
176 competitors in Obesity
#DrugCompanyPhaseTrials
1Spiriva
Boehringer IngelheimApproved
Vivia
SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Phase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Enavogliflozin
Daewoong Pharmaceutical Co. LTD.Phase 3
Retatrutide
Eli LillyPhase 3
Mibavademab
RegeneronPhase 3
Eloralintide
Eli LillyPhase 3
Naltrexone-Bupropion Combination
CCurrax Pharmaceuticals
Phase 3
Survodutide
Boehringer IngelheimPhase 3
Semaglutide or Tirzepatide
NNational and Kapodistrian University of Athens
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Obstructive Pulmonary Disease16 trials
Show 13 more trials
Asthma8 trials
Show 5 more trials
The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations
Terminated·—·N/A·NCT00706446·255 enrolled
COPD3 trials
Tiotropium Handihaler vs. Tiotropium Respimat in COPD
Withdrawn·—·Phase 2·NCT05838703
COPD Exacerbation2 trials
18 more indications
Tolerance2 trials
Treatment1 trial
Quality of Life1 trial
Dyspnea1 trial
Salmeterol1 trial
Cystic Fibrosis1 trial
Cardiovascular Disease1 trial
Atopic Asthma1 trial
Unspecified3 trials
Methacholine, Long-acting M-cholinolytic and beta2-agonist on the Activity of Beta-receptors in Healthy Volunteers
Unknown status·—·N/A·NCT04137029·20 enrolled
Regulatory
FDA Approval Timeline[5]
Jan 30, 2004
SPIRIVA
NDA NDA021395
Sep 15, 2015
SPIRIVA RESPIMAT
NDA NDA021936
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Spiriva drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Tiotropium Bromide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Muscarinic Acetylcholine Receptor M3 Antagonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company